McDermott Advises Innate Pharma in Expanding its Collaboration with AstraZeneca
PARIS – McDermott Will & Emery advised Innate Pharma, a French company operating in the field of oncology, in signing a multi-term agreement with AstraZeneca and MedImmune – its research and development branch of biological molecules. This agreement broadens the existing collaboration, aimed at accelerating the development of an oncology portfolio of each of the parties and to provide patients with more rapid access to new therapeutic options.
This extended collaboration will permit Innate Pharma to develop and commercially strengthen its investment ability to develop its immuno-oncology portfolio (IO) and its R&D platform. For its part, AstraZeneca will enrich its IO portfolio with new clinical and preclinical programs.
Following on from this agreement, Innate Pharma licenses the commercial rights in the United States and in Europe for Lumoxiti, a treatment against Hairy Cell Leukemia developed by AstraZeneca, recently approved by the FDA. AstraZeneca shall obtain all of the oncology rights in the humanized antibody “first-in-class” anti-NKG2A, monalizumab, extending the partnership initially announced in 2015.
Innate Pharma is a French company founded in 1999 and based in Marseille. It is involved in the field of oncology, the medical specialty tied to cancer.
About McDermott Will & Emery McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, San Francisco, Seoul, Silicon Valley and Washington, DC. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.